MaxCyte (MXCT) announced it has signed a strategic platform license, SPL, with Adicet Bio, a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXCT: